Lenalidomide Overcomes the Resistance to Third-Generation CD19-CAR-T Cell Therapy in Preclinical Models of Diffuse Large B-Cell Lymphoma

Germinal center B-cell-like diffuse large B-cell lymphoma cell line OCI-Ly1, and patient-derived xenografted mice were used as the CAR-T cell-resistant model.